Brind.

German drug pricing reform is causing Eli Lilly and Boehringer Ingelheim to withdraw from European markets.

1 report, 1 independent Updated Jun 6

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Eli Lilly and Company Boehringer Ingelheim

Keep exploring

The entities involved

Eli Lilly and Company
American pharmaceutical company
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Sun 16:06
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.Sun 10:21
Boehringer Ingelheim
German pharmaceutical company

Nothing else this week.

Related events

Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.Aug 5

Coverage

Newest first; wire copies grouped

Jun 6yahoo.com